Organization (Industry)
Spectrum Pharmaceuticals (United States)
ClinicalTrials.gov lists Spectrum Pharmaceuticals (United States) as lead sponsor of 60 trials. It has 12 active development programs and 25 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Spectrum Pharmaceuticals, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Spectrum Pharmaceuticals (United States): 60 lead-sponsored trials and 1 legal-entity registration.
Disease areas (59)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lymphoma | 25 |
| Lymphoma, Non-Hodgkin | 24 |
| Breast Neoplasms | 10 |
| Lung Neoplasms | 9 |
| Carcinoma, Non-Small-Cell Lung | 8 |
Showing 5 of 59 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 7 |
| 2016 | 6 |
| 2015 | 3 |
| 2014 | 1 |
| 2013 | 6 |
Showing 10 of 22 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (12)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| CYCLOPHOSPHAMIDE | Neutropenia | Phase 3 | 4 |
| DOCETAXEL | Neutropenia | Phase 3 | 4 |
| DOCETAXEL | Breast Neoplasms | Phase 3 | 3 |
| CYCLOPHOSPHAMIDE | Breast Neoplasms | Phase 3 | 3 |
| AG chemotherapy | Lymphoma | Phase 2 | 1 |
Showing 5 of 12 active programs.
Approved assets (25)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DOCETAXEL | 7 |
| CYCLOPHOSPHAMIDE | 4 |
| SPI-2012 | 4 |
| PEGFILGRASTIM | 3 |
| RITUXIMAB | 3 |
Showing 5 of 25 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 35% hit target (n=20) | 75% on time (n=20) |
Journals published in (23)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 7 |
| British journal of haematology | 2 |
| Journal of clinical pharmacology | 2 |
| Blood | 1 |
| Cancer cell | 1 |
Showing 5 of 23 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 52 | 11 | 2025-11-25 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 7 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Spectrum Pharmaceuticals, Inc. | Boston, US | FDA |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| M.D. Anderson Cancer Center | Co sponsors trial with | 4 |
| Valerio Therapeutics | Co sponsors trial with | 3 |
| The Leukemia and Lymphoma Society | Co sponsors trial with | 1 |
| Therapeutic Advances in Childhood Leukemia Consortium | Co sponsors trial with | 1 |
| Cephalon | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (142)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-25 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-07-08 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-06-03 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-05-06 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-01-21 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 142 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| SPECTRUM | Certificate of waiver | Terminated |
Biomarker capability evidence (209)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC6 | Trial collaborator | Named in trial inclusion criteria |
| ALK | Trial collaborator | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial collaborator | Named in trial inclusion criteria |
| CD34 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 209 evidence rows.
On Scientist.com
Spectrum Pharmaceuticals (United States) is linked to 2 research suppliers in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, and biomarkers this organization publishes on.
Work with Spectrum Pharmaceuticals on Scientist.com
For prices, more details, or to contact Spectrum Pharmaceuticals, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.